LC
CDLX icon

Lindbrook Capital’s Cardlytics CDLX Stock Holding History

Lindbrook Capital’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25
Closed -$2.08K – 2835
2024
Q2 		$2.08K Buy
25
+5
+25% +$541 ﹤0.01% 2330
2024
Q1 		$2.87K Buy
20
+9
+82% +$760 ﹤0.01% 2115
2023
Q4 		$1.03K Sell
11
-2
-15% -$203 ﹤0.01% 2456
2023
Q3 		$2.1K Buy
+13
New +$1.69K ﹤0.01% 2111
2022
Q4 		– Sell
-2
Closed – – 2852
2022
Q3 		$0 Sell
2
-3
-60% -$427 ﹤0.01% 2643
2022
Q2 		$1K Sell
5
-2
-29% -$670 ﹤0.01% 2176
2022
Q1 		$4K Buy
7
+4
+133% +$2.42K ﹤0.01% 1679
2021
Q4 		$2K Hold
3
– – ﹤0.01% 1751
2021
Q3 		$3K Hold
3
– – ﹤0.01% 1384
2021
Q2 		$4K Hold
3
– – ﹤0.01% 1346
2021
Q1 		$4K Hold
3
– – ﹤0.01% 1310
2020
Q4 		$5K Hold
3
– – ﹤0.01% 1166
2020
Q3 		$2K Hold
3
– – ﹤0.01% 1368
2020
Q2 		$2K Buy
+3
New +$1.73K ﹤0.01% 1365

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lindbrook Capital's CDLX Position: Q3 2024 in Review

Lindbrook Capital sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 25 shares — an estimated $2.08K sold.

Lindbrook Capital first reported a position in CDLX in Q2 2020 and held it in 14 quarters. The position peaked at $5K in Q4 2020. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

  • Lindbrook Capital reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
  • Lindbrook Capital sold 25 Cardlytics shares in Q3 2024, an estimated $2.08K.
  • Lindbrook Capital first reported a position in Cardlytics in Q2 2020 and held it in 14 quarters.
  • Lindbrook Capital's Cardlytics position peaked at $5K in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.